Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?
1 Answers
Mednet Member
Medical Oncology · Cedars-Sinai Medical Center
The PACIFIC trial did not evaluate this regimen in patients with performance status 2-3. Durvalumab dosing does not change based on toxicity. I do not use this regimen for patients with PS 2-3 without supporting data at this time.